Immune Pharmaceuticals Inc. (IMNP) Sees Large Growth in Short Interest

Immune Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Kazado Daniel has acquired 76,503 shares of Immune Pharmaceuticals, Inc.

Moving toward technical analysis, the current ratio, or the liquidity ratio of a company was calculated 2.90 as compared to its debt to equity ratio stands at 0.31.

If we glance over stock price target, the analysts were fairly in stock's favor assigning high price target of 4 and average price target of 4. (NASDAQ:IMNP) is 0.95. The Average Volume (3 months) is 5.96 Million.

Some buy side analysts are also providing their Analysis on Immune Pharmaceuticals, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. The stock was last seen -0.75% lower, reaching at $0.18 on February 21, 2017. Immune Pharmaceuticals has a 12 month low of $0.16 and a 12 month high of $0.83. (NASDAQ:IMNP) where ROTH Capital provided Buy rating on the stock on 8-Oct-15. (NASDAQ:IMNP)'s stock to Buy with the price target of $5.5. Vanguard Group Inc owns $741 thousand in Immune Pharmaceuticals, Inc., which represents roughly 2.36% of the company's market cap and approximately 74.1% of the institutional ownership.

For the quarter ending 08/15/2016, The Analyst projected that the company could deliver EPS of -0.13 while the company provided its Actual EPS of -0.13 showing a difference of 0 Percent between the Estimated and Actual EPS. (NASDAQ:IMNP) could bring EPS of $-0.14/share. The company has a 1 Year high price target of $3.

06/11/2015 - MLV & Co began new coverage on Immune Pharmaceuticals Inc giving the company a "buy" rating.

Over the past five trading sessions shares of PharmAthene, Inc. The stock is now moving above its 20-Day Simple Moving Average of -6.74% with the 50-Day Simple Moving Average of -6.74 percent. Current price places the company's stock -65.69% away from its 200-day simple moving average, -66.83%, away from the 50-day average and also -52.86% away from 20-day average.

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) is now showing its ROA (Return on Assets) of -112.1%. Over the past five trading sessions it is -7.91%; -15.7% for the month; -1.49% for the last quarter; -54.63% for the past six-months; and -60.82% for the last 12 months.

While looking at the Stock's Performance, Immune Pharmaceuticals, Inc. now shows a Weekly Performance of -2.39%, where Monthly Performance is -14.61%, Quarterly performance is -5.26%, 6 Months performance is -52.63% and yearly performance percentage is -58.14%. The stock is performing -72% year to date. The stock is showing its Operating Margin of 0 percent.